Toll-like Receptors

ETI41 is a selective Toll-like receptor (TLR) inhibitor that targets the nucleoside-binding Site I on TLR7 and TLR9, demonstrating IC50 values of 0.63 μM and 0.16 μM, respectively, while sparing surface TLRs. This compound effectively inhibits endosomal TLR-mediated pro-inflammatory signaling, displaying potent nanomolar activity across cellular, biophysical, and in vivo assays. ETI41 suppresses the expression of inflammation-associated genes and improves symptoms in murine models of psoriasis and systemic lupus erythematosus (SLE). It is valuable for research into autoimmune and inflammatory diseases.

M199 is a selective inhibitor of TLR3 and TLR9 signaling pathways. This compound effectively induces the secretion of pro-inflammatory cytokines, including IL-6, IL-8, and TNFα, in human peripheral blood mononuclear cells (PBMCs). M199 is utilized in research to investigate immune response modulation and the role of TLR signaling in various biological processes.

HCN-IN-1 is a TLR4 inhibitor and modulator of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, specifically targeting HCN2 and HCN4. It effectively inhibits TLR4-mediated signaling, evidenced by reduced alkaline phosphatase activity. HCN-IN-1 modulates HCN2 currents by shifting the voltage-dependent activation to hyperpolarized potentials and slowing activation kinetics, while also blocking currents through HCN4 channels. This compound demonstrates significant analgesic, anti-inflammatory, and anti-anginal properties, making it valuable for research into inflammatory pain, neuropathic pain, heart failure, and related inflammatory conditions.